X4 Pharmaceuticals (XFOR) Stock Forecast, Price Target & Predictions
XFOR Stock Forecast
X4 Pharmaceuticals stock forecast is as follows: an average price target of $3.67 (represents a 809.54% upside from XFOR’s last price of $0.40) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
XFOR Price Target
The average price target for X4 Pharmaceuticals (XFOR) is $3.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $3.00. This represents a potential 809.54% upside from XFOR's last price of $0.40.
XFOR Analyst Ratings
According to 3 Wall Street analysts, X4 Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for XFOR stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
X4 Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 22, 2022 | - | Cantor Fitzgerald | $3.00 | $0.85 | 252.98% | 643.49% |
| Dec 11, 2022 | Edward Tenthoff | Piper Sandler | $3.00 | $0.93 | 222.58% | 643.49% |
| Nov 30, 2022 | - | H.C. Wainwright | $5.00 | $1.85 | 170.27% | 1139.16% |
The latest X4 Pharmaceuticals stock forecast, released on Dec 22, 2022 by Cantor Fitzgerald company, set a price target of $3.00, which represents a 252.98% increase from the stock price at the time of the forecast ($0.85), and a 643.49% increase from XFOR last price ($0.40).
X4 Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.40 | $0.40 | $0.40 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of X4 Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to X4 Pharmaceuticals's last price of $0.40. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 22, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
| Dec 11, 2022 | Piper Sandler | - | Overweight | Initialise |
X4 Pharmaceuticals's last stock rating was published by H.C. Wainwright on Jun 28, 2024. The company gave XFOR a "Buy" rating, the same as its previous rate.
X4 Pharmaceuticals Financial Forecast
X4 Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 22 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $3.00M |
| Avg Forecast | $5.20M | $4.43M | $3.17M | $2.53M | $1.03M | $1.69M | $15.27M | $128.57K | $4.29M |
| High Forecast | $11.55M | $9.84M | $7.03M | $2.60M | $3.44M | $1.69M | $15.27M | $128.57K | $5.14M |
| Low Forecast | $2.69M | $2.30M | $1.64M | $2.46M | $245.09K | $1.68M | $15.27M | $128.57K | $3.43M |
| # Analysts | 1 | 1 | 1 | 2 | 6 | 3 | 3 | 9 | 20 |
| Surprise % | - | - | - | - | - | - | - | - | 0.70% |
X4 Pharmaceuticals's average Quarter revenue forecast for Mar 22 based on 9 analysts is $128.57K, with a low forecast of $128.57K, and a high forecast of $128.57K. XFOR's average Quarter revenue forecast represents a -95.71% decrease compared to the company's last Quarter revenue of $3.00M (Mar 20).
X4 Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 22 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 6 | 3 | 3 | 9 | 20 |
| EBITDA | - | - | - | - | - | - | - | $-21.58M | $-10.37M |
| Avg Forecast | $3.12M | $2.66M | $1.90M | $1.52M | $620.00K | $1.01M | $9.16M | $-17.84M | $-13.48M |
| High Forecast | $6.93M | $5.91M | $4.22M | $1.56M | $2.07M | $1.01M | $9.16M | $-14.27M | $-10.78M |
| Low Forecast | $1.62M | $1.38M | $983.92K | $1.48M | $147.05K | $1.01M | $9.16M | $-21.41M | $-16.18M |
| Surprise % | - | - | - | - | - | - | - | 1.21% | 0.77% |
undefined analysts predict XFOR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than X4 Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
X4 Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 22 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 6 | 3 | 3 | 9 | 20 |
| Net Income | - | - | - | - | - | - | - | $-21.96M | $-11.14M |
| Avg Forecast | $-26.11M | $-26.11M | $-26.11M | $-29.46M | $-31.80M | $-34.43M | $-1.43M | $-20.32M | $-14.48M |
| High Forecast | $-9.75M | $-9.75M | $-9.75M | $-27.62M | $-24.32M | $-12.85M | $-535.47K | $-16.25M | $-11.58M |
| Low Forecast | $-67.54M | $-67.54M | $-67.54M | $-31.30M | $-35.55M | $-89.07M | $-3.71M | $-24.38M | $-17.38M |
| Surprise % | - | - | - | - | - | - | - | 1.08% | 0.77% |
X4 Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. XFOR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
X4 Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 22 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 6 | 3 | 3 | 9 | 20 |
| SG&A | - | - | - | - | - | - | - | $7.66M | $4.67M |
| Avg Forecast | $11.42M | $9.74M | $6.95M | $5.56M | $2.27M | $3.70M | $33.52M | $282.36K | $9.41M |
| High Forecast | $25.36M | $21.62M | $15.44M | $5.72M | $7.56M | $3.71M | $33.52M | $282.36K | $11.29M |
| Low Forecast | $5.91M | $5.04M | $3.60M | $5.41M | $538.24K | $3.70M | $33.52M | $282.36K | $7.53M |
| Surprise % | - | - | - | - | - | - | - | 27.14% | 0.50% |
X4 Pharmaceuticals's average Quarter SG&A projection for Jun 24 is $33.52M, based on 3 Wall Street analysts, with a range of $33.52M to $33.52M. The forecast indicates a 337.43% rise compared to XFOR last annual SG&A of $7.66M (Mar 22).
X4 Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 22 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 6 | 3 | 3 | 9 | 20 |
| EPS | - | - | - | - | - | - | - | $-0.65 | $-0.56 |
| Avg Forecast | $-0.13 | $-0.13 | $-0.13 | $-0.15 | $-0.16 | $-0.17 | $-0.01 | $-0.60 | $-0.79 |
| High Forecast | $-0.05 | $-0.05 | $-0.05 | $-0.14 | $-0.12 | $-0.06 | $-0.00 | $-0.60 | $-0.79 |
| Low Forecast | $-0.34 | $-0.34 | $-0.34 | $-0.16 | $-0.18 | $-0.44 | $-0.02 | $-0.60 | $-0.79 |
| Surprise % | - | - | - | - | - | - | - | 1.08% | 0.71% |
According to undefined Wall Street analysts, X4 Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to XFOR previous annual EPS of $NaN (undefined).
X4 Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.68 | $70.00 | 10194.12% | Buy |
| ELEV | Elevation Oncology | $0.53 | $9.00 | 1598.11% | Buy |
| XFOR | X4 Pharmaceuticals | $0.40 | $3.67 | 817.50% | Buy |
| INZY | Inozyme Pharma | $3.13 | $14.67 | 368.69% | Buy |
| PDSB | PDS Bio | $2.01 | $9.00 | 347.76% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.40 | $7.00 | 191.67% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.31 | $38.80 | 191.51% | Buy |
| TERN | Terns Pharmaceuticals | $6.17 | $14.25 | 130.96% | Buy |
| MREO | Mereo BioPharma Group | $3.53 | $6.75 | 91.22% | Buy |
| HOOK | HOOKIPA Pharma | $3.00 | $3.00 | - | Buy |
| EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |